The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
Official Title: An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)
Study ID: NCT04952753
Brief Summary: The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanisms of action may reverse resistance and improve responsiveness to the currently considered SOC anti-cancer therapy in the second line metastatic colorectal cancer (mCRC) setting.
Detailed Description: This is an open-label, multi-center, phase II, 2-part platform study with Safety run-in and Expansion parts. The platform design of this study is adaptive to allow flexibility in the introduction of additional treatment arms with new investigational drugs in combination with SOC anti-cancer therapy for the second line treatment of mCRC. The study will include a control arm that will enroll participants treated with SOC anti-cancer therapy (bevacizumab with mFOLFOX6 or FOLFIRI) for the second line treatment of mCRC. The choice of the chemotherapy medications (mFOLFOX6 or FOLFIRI) will be determined by the Investigator based on prior exposure to oxaliplatin or irinotecan. Each investigational arm will include a combination of an investigational drug and the SOC anti-cancer therapy. The first investigational arm of the study will explore the combination of anti-transforming growth factor β (TGF-β) monoclonal antibody, NIS793 with SOC anti-cancer therapy. The second investigational arm of the study will explore the combination of anti-transforming growth factor β (TGF-β) monoclonal antibody, NIS793 with Tislelizumab, which is an anti-PD1 monoclonal antibody, and SOC anti-cancer therapy. Combination of other investigational drugs with SOC anti-cancer therapy may be added by protocol amendments an additional investigational arms. In each investigational arm, a Safety run-in part will be conducted before opening the expansion part to confirm the recommended phase 2 dose (RP2D) for a combination of any investigational drug with SOC anti-cancer therapy unless the dose has been confirmed externally to this trial. The decision to open the Expansion part of the study will be based on dose confirmation of investigational drug with available safety, relevant PK and other relevant data from Safety run-in part. Participants in the expansion part will be randomized in 1:2 ratio to the control arm or investigational arm.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The Angeles Clinic and Research Institute ., Los Angeles, California, United States
University of Michigan Medical ., Ann Arbor, Michigan, United States
WA Uni School Of Med ., Saint Louis, Missouri, United States
Astera Cancer Center, East Brunswick, New Jersey, United States
Sarah Cannon Research Institute DeptofSarahCannonRes Inst 2, Nashville, Tennessee, United States
Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States
Mays Cancer Center, San Antonio, Texas, United States
Novartis Investigative Site, Adelaide, South Australia, Australia
Novartis Investigative Site, Bendigo, Victoria, Australia
Novartis Investigative Site, Perth, Western Australia, Australia
Novartis Investigative Site, Bruxelles, , Belgium
Novartis Investigative Site, Bruxelles, , Belgium
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Brampton, Ontario, Canada
Novartis Investigative Site, Cambridge, Ontario, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Brno, Czech Republic, Czechia
Novartis Investigative Site, Hradec Kralove, CZE, Czechia
Novartis Investigative Site, Praha 4, , Czechia
Novartis Investigative Site, Avignon, , France
Novartis Investigative Site, Creteil, , France
Novartis Investigative Site, Nantes Cedex 1, , France
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Bochum, , Germany
Novartis Investigative Site, Dresden, , Germany
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Frankfurt, , Germany
Novartis Investigative Site, Hamburg, , Germany
Novartis Investigative Site, Ulm, , Germany
Novartis Investigative Site, Pokfulam, , Hong Kong
Novartis Investigative Site, Shatin New Territories, , Hong Kong
Novartis Investigative Site, Haifa, , Israel
Novartis Investigative Site, Petach Tikva, , Israel
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Nagoya, Aichi, Japan
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan
Novartis Investigative Site, Osaka-city, Osaka, Japan
Novartis Investigative Site, Toyama-city, Toyama, Japan
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Sabadell, Barcelona, Spain
Novartis Investigative Site, Santander, Cantabria, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, St. Gallen, , Switzerland
Novartis Investigative Site, Tainan, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Aberdeen, Scotland, United Kingdom
Novartis Investigative Site, Cambridge, , United Kingdom
Novartis Investigative Site, Oxford, , United Kingdom
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR